A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms CONQUER
- Sponsors Eli Lilly and Company
- 16 Oct 2019 Status changed from active, no longer recruiting to completed.
- 11 Oct 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 06 Oct 2019 This trial was completed in Spain and Hungary (end date: 2019-09-19), according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History